Review

wm115 (ATCC)

ATCC is a verified supplier

ATCC manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATCC wm115
Wm115, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 445 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/wm115/MES-SA%2FMX2%3B+Uterine+Sarcoma%3B+Human/us12497385-1837-6-7
Average 96 stars, based on 445 article reviews

wm115 - by Bioz Stars, 2026-10

96/100 stars

Images

Cell Culture:

Article Title: Malassezin and analogs thereof as skin brightening agents
Article Snippet: Materials and Reagents Annexin V-FITC assay kit was purchased from Beyotime Biotechnology, RPMI 1640 medium and Dulbecco's modified Eagle medium (“DMEM”) were purchased from Gibco, fetal bovine serum (“FBS”) was purchased from Invitrogen, stabilized antibiotic antimycotic solution (100×) was purchased from Sigma, and 0.25% trypsin-EDTA (1×), phenol red was purchased from Invitrogen. .. Cell Culture MeWo (ATCC® HTB-65TM) and WM115 (ATCC® CRL-1675) cells were purchased from ATCC (Manassas, VA) and maintained in the following: for MeWo: DMEM supplemented with 10% FBS; for WM115: RPMI 1640 supplemented with 10% FBS (10% FBS, 1% stabilized antibiotic anti-mycotic solution). ..

Article Title: Photoprotective compositions containing
Article Snippet: Materials and Reagents Annexin V-FITC assay kit was purchased from Beyotime Biotechnology, RPMI 1640 medium and Dulbecco's modified Eagle medium (“DMEM”) were purchased from Gibco, fetal bovine serum (“FBS”) was purchased from Invitrogen, stabilized antibiotic antimycotic solution (100×) was purchased from Sigma, and 0.25% trypsin-EDTA (IX), phenol red was purchased from Invitrogen. .. Cell Culture MeWo (ATCC® HTB-65TM) and WM115 (ATCC® CRL-1675) cells were purchased from ATCC (Manassas, VA) and maintained in the following: for MeWo: DMEM supplemented with 10% FBS; for WM115: RPMI 1640 supplemented with 10% FBS (10% FBS, 1% stabilized antibiotic antimycotic solution). ..

Article Title: Extracellular vesicles of Janthinobacterium lividum as violacein carriers in melanoma cell treatment
Article Snippet: .. In vitro studies were performed on keratinocytes: HaCaT cells (300493, Cytion, Eppelheim, Germany) cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 4.5 g/l glucose and 2 mM l -glutamine (VWR, Radnor, PA, USA) and three melanoma cell lines: WM35 (CRL-2807, ATCC, Manassas, VA, USA), WM115 (CRL-1675, ATCC, Manassas, VA, USA) and A375-P (CRL-3224, ATCC, Manassas, VA, USA) cultured in Roswell Park Memorial Institute medium 1640 (RPMI-1640; VWR, Radnor, PA, USA). .. All culture media were supplemented with 10% (v/v) fetal bovine serum (FBS, Life Technologies part of Thermo Fisher Scientific, Waltham, MA, USA) and antibiotics (100 U/ml penicillin, 0.25 μg/ml streptomycin, Life Technologies part of Thermo Fisher Scientific, Waltham, MA, USA).

In Vitro:

Modification:

Image Search Results

AHR and ARNT regulate basal HLA-II expression on cancer cells. A Western blot analysis confirming AHR or ARNT overexpression (OE) in A375, WM115, and SKMEL2 melanoma cell lines. Protein levels of AHR, ARNT, and HLA-DRA were assessed using anti-AHR (clone D5S6H), anti-ARNT (clone D28F3), and polyclonal anti–HLA-DRA antibodies, respectively, with β-tubulin detected using an anti–β-tubulin antibody (clone C66) as a loading control. B- C Flow cytometry analysis of surface pan–HLA-II expression in A375, WM115, and SKMEL2 cells overexpressing AHR or ARNT. Representative histograms from three independent experiments show pan–HLA-II expression, with dashed lines indicating the median of the empty vector control group ( B ). The gMFI was quantified across three independent experiments, normalized to the empty vector control group, and presented as fold change ( C ). D Western blot analysis of AHR, ARNT, and HLA-DRA protein levels in AHR or ARNT reconstituted A375 cells generated by reintroducing AHR or ARNT into respective KO cells. Protein levels of AHR, ARNT, and HLA-DRA were assessed using anti-AHR (clone D5S6H), anti-ARNT (clone D28F3), and polyclonal anti–HLA-DRA antibodies, respectively, with β-tubulin detected using an anti–β-tubulin antibody (clone C66) as a loading control. E - F Flow cytometry analysis of surface pan–HLA-II expression in AHR- or ARNT-reconstituted A375 cells. Representative histograms from three independent experiments show pan–HLA-II expression ( E ). The gMFI was quantified across three independent experiments, normalized to the NTC group, and presented as fold change ( F ). Surface pan–HLA-II expression was detected using APC anti-human HLA-DR, DP, DQ Antibody (clone Tü39) ( B - C and E - F ). Data are represented as mean ± SD ( C and F ). Statistical analysis by one-way ANOVA ( C ) and unpaired Student’s t-test ( F ); * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. vec, empty vector control

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: The aryl hydrocarbon receptor (AHR) drives human leukocyte antigen (HLA)-II expression in human melanoma

doi: 10.1186/s13046-026-03673-y

Figure Lengend Snippet: AHR and ARNT regulate basal HLA-II expression on cancer cells. A Western blot analysis confirming AHR or ARNT overexpression (OE) in A375, WM115, and SKMEL2 melanoma cell lines. Protein levels of AHR, ARNT, and HLA-DRA were assessed using anti-AHR (clone D5S6H), anti-ARNT (clone D28F3), and polyclonal anti–HLA-DRA antibodies, respectively, with β-tubulin detected using an anti–β-tubulin antibody (clone C66) as a loading control. B- C Flow cytometry analysis of surface pan–HLA-II expression in A375, WM115, and SKMEL2 cells overexpressing AHR or ARNT. Representative histograms from three independent experiments show pan–HLA-II expression, with dashed lines indicating the median of the empty vector control group ( B ). The gMFI was quantified across three independent experiments, normalized to the empty vector control group, and presented as fold change ( C ). D Western blot analysis of AHR, ARNT, and HLA-DRA protein levels in AHR or ARNT reconstituted A375 cells generated by reintroducing AHR or ARNT into respective KO cells. Protein levels of AHR, ARNT, and HLA-DRA were assessed using anti-AHR (clone D5S6H), anti-ARNT (clone D28F3), and polyclonal anti–HLA-DRA antibodies, respectively, with β-tubulin detected using an anti–β-tubulin antibody (clone C66) as a loading control. E - F Flow cytometry analysis of surface pan–HLA-II expression in AHR- or ARNT-reconstituted A375 cells. Representative histograms from three independent experiments show pan–HLA-II expression ( E ). The gMFI was quantified across three independent experiments, normalized to the NTC group, and presented as fold change ( F ). Surface pan–HLA-II expression was detected using APC anti-human HLA-DR, DP, DQ Antibody (clone Tü39) ( B - C and E - F ). Data are represented as mean ± SD ( C and F ). Statistical analysis by one-way ANOVA ( C ) and unpaired Student’s t-test ( F ); * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. vec, empty vector control

Article Snippet: After 48 h of transfection, cells that had been transduced were selected using 0.7 μg/ml (A375) or 0.6 μg/ml (WM115) of puromycin (InvivoGen #ant-pr-1) for 3 days.

Techniques: Expressing, Western Blot, Over Expression, Control, Flow Cytometry, Plasmid Preparation, Generated

Ligand-mediated activation of AHR regulates HLA-II expression on cancer cells. A Flow cytometry analysis of surface pan–HLA-II expression in A375, WM115, and SKMEL2 melanoma cells following 72-hour treatment with 2.5 μM GNF351 (AHR antagonist), 1 μM FICZ (AHR agonist), 100 ng/mL IFN-γ, or 0.1% DMSO (vehicle control). B - C Time-course analysis of pan–HLA-II surface expression in A375, WM115, and SKMEL2 cells following treatment with GNF351 (2.5 μM) or FICZ (1 μM) for 24, 48, or 72 hours. D - E pan–HLA-II expression in A375 cells at 72 hours post drug withdrawal following prior exposure to 2.5 μM GNF351 or 1 μM FICZ for 24, 48, or 72 hours. F - G Surface pan–HLA-II expression in WM115 ( F ) and SKMEL2 ( G ) cells at multiple timepoints post drug withdrawal, following treatment as in ( D - E ). H - I Surface pan–HLA-II expression in AHR or ARNT KO WM115 ( H ) and SKMEL2 ( I ) after 72-hour treatment with 1 μM FICZ or DMSO control. Surface pan–HLA-II expression was detected using APC anti-human HLA-DR, DP, DQ Antibody (clone Tü39). Representative histograms from three independent experiments show pan–HLA-II expression, with dashed lines indicating the median of the DMSO control group ( A , B and D ). The gMFI was quantified across three independent experiments, normalized to the DMSO control group ( C and E - G ) or to the mean of the two NTC sgRNAs with DMSO treatment ( H - I ), and presented as fold change. Data are represented as mean ± SD ( C and E - I ). Statistical analysis by one-way ANOVA (C and E); * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: The aryl hydrocarbon receptor (AHR) drives human leukocyte antigen (HLA)-II expression in human melanoma

doi: 10.1186/s13046-026-03673-y

Figure Lengend Snippet: Ligand-mediated activation of AHR regulates HLA-II expression on cancer cells. A Flow cytometry analysis of surface pan–HLA-II expression in A375, WM115, and SKMEL2 melanoma cells following 72-hour treatment with 2.5 μM GNF351 (AHR antagonist), 1 μM FICZ (AHR agonist), 100 ng/mL IFN-γ, or 0.1% DMSO (vehicle control). B - C Time-course analysis of pan–HLA-II surface expression in A375, WM115, and SKMEL2 cells following treatment with GNF351 (2.5 μM) or FICZ (1 μM) for 24, 48, or 72 hours. D - E pan–HLA-II expression in A375 cells at 72 hours post drug withdrawal following prior exposure to 2.5 μM GNF351 or 1 μM FICZ for 24, 48, or 72 hours. F - G Surface pan–HLA-II expression in WM115 ( F ) and SKMEL2 ( G ) cells at multiple timepoints post drug withdrawal, following treatment as in ( D - E ). H - I Surface pan–HLA-II expression in AHR or ARNT KO WM115 ( H ) and SKMEL2 ( I ) after 72-hour treatment with 1 μM FICZ or DMSO control. Surface pan–HLA-II expression was detected using APC anti-human HLA-DR, DP, DQ Antibody (clone Tü39). Representative histograms from three independent experiments show pan–HLA-II expression, with dashed lines indicating the median of the DMSO control group ( A , B and D ). The gMFI was quantified across three independent experiments, normalized to the DMSO control group ( C and E - G ) or to the mean of the two NTC sgRNAs with DMSO treatment ( H - I ), and presented as fold change. Data are represented as mean ± SD ( C and E - I ). Statistical analysis by one-way ANOVA (C and E); * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

Article Snippet: After 48 h of transfection, cells that had been transduced were selected using 0.7 μg/ml (A375) or 0.6 μg/ml (WM115) of puromycin (InvivoGen #ant-pr-1) for 3 days.

Techniques: Activation Assay, Expressing, Flow Cytometry, Control

AHR signaling modulates HLA-II expression via transcriptional regulation of CIITA. A - B Scatterplots showing differentially expressed genes in A375 cells with CRSIPR-mediated knockouts of AHR ( A ) or ARNT ( B ) compared to NTC cells. Significantly downregulated (blue) and upregulated (red) genes are defined by adjusted p < 0.0001 and |log2 fold change| > 0.5. The top 20 differentially expressed genes are indicated. C Correlation analysis of gene expression changes between AHR KO and ARNT KO groups. Each point represents a gene; commonly upregulated (red) and downregulated (blue) genes are highlighted, with CYP1A1 and HLA-II-related genes indicated. D - E Venn diagrams showing the overlap of significantly downregulated ( D ) and upregulated genes ( E ) between AHR KO and ARNT KO groups. F Heatmap showing the common significantly downregulated and upregulated genes in AHR KO, ARNT KO, and NTC samples of A375, with HLA-II genes and cellular stress and signaling response genes indicated. G - H KEGG pathway enrichment analysis of common significantly downregulated genes ( G ) and upregulated genes ( H ) in AHR KO and ARNT KO groups. I Scatterplot showing differentially expressed genes in WM115 cells treated with 1 μM FICZ for 72 h compared to the 0.1% DMSO control group. Significantly downregulated (blue) and upregulated (red) genes are defined by adjusted p < 0.01 and |log2 fold change| > 0.5. HLA-II-related genes are indicated. J Heatmap of differentially expressed genes in WM115 cells with FICZ versus DMSO control, with HLA-II-related genes annotated. K KEGG analysis of significantly upregulated genes in the FICZ-treated group compared to the DMSO control group of WM115. Statistical analysis by t-test (C) and hypergeometric test (G-H and K). PCC, Pearson correlation coefficient

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: The aryl hydrocarbon receptor (AHR) drives human leukocyte antigen (HLA)-II expression in human melanoma

doi: 10.1186/s13046-026-03673-y

Figure Lengend Snippet: AHR signaling modulates HLA-II expression via transcriptional regulation of CIITA. A - B Scatterplots showing differentially expressed genes in A375 cells with CRSIPR-mediated knockouts of AHR ( A ) or ARNT ( B ) compared to NTC cells. Significantly downregulated (blue) and upregulated (red) genes are defined by adjusted p < 0.0001 and |log2 fold change| > 0.5. The top 20 differentially expressed genes are indicated. C Correlation analysis of gene expression changes between AHR KO and ARNT KO groups. Each point represents a gene; commonly upregulated (red) and downregulated (blue) genes are highlighted, with CYP1A1 and HLA-II-related genes indicated. D - E Venn diagrams showing the overlap of significantly downregulated ( D ) and upregulated genes ( E ) between AHR KO and ARNT KO groups. F Heatmap showing the common significantly downregulated and upregulated genes in AHR KO, ARNT KO, and NTC samples of A375, with HLA-II genes and cellular stress and signaling response genes indicated. G - H KEGG pathway enrichment analysis of common significantly downregulated genes ( G ) and upregulated genes ( H ) in AHR KO and ARNT KO groups. I Scatterplot showing differentially expressed genes in WM115 cells treated with 1 μM FICZ for 72 h compared to the 0.1% DMSO control group. Significantly downregulated (blue) and upregulated (red) genes are defined by adjusted p < 0.01 and |log2 fold change| > 0.5. HLA-II-related genes are indicated. J Heatmap of differentially expressed genes in WM115 cells with FICZ versus DMSO control, with HLA-II-related genes annotated. K KEGG analysis of significantly upregulated genes in the FICZ-treated group compared to the DMSO control group of WM115. Statistical analysis by t-test (C) and hypergeometric test (G-H and K). PCC, Pearson correlation coefficient

Article Snippet: After 48 h of transfection, cells that had been transduced were selected using 0.7 μg/ml (A375) or 0.6 μg/ml (WM115) of puromycin (InvivoGen #ant-pr-1) for 3 days.

Techniques: Expressing, Gene Expression, Control

AHR-ARNT complex binds CIITA promoter II to drive HLA-II transcription. A - B Genome browser tracks showing gene CIITA mRNA expression (RNA-Seq) across the CIITA locus in A375 with sgNTC, sgAHR, or sgARNT (A) and in WM115 cells treated with 1 μM FICZ or 0.1% DMSO for 72 h (B). C - D ATAC-seq tracks showing chromatin accessibility at the CIITA locus in A375 cells with sgNTC, sgAHR, or sgARNT ( C ) and in WM115 cells treated with 1 μM FICZ or 0.1% DMSO for 72 h ( D ). E - F ChIP-seq tracks showing AHR or ARNT binding at the CIITA locus in SKMEL2 cells expressing empty vector control, 3×HA-AHR overexpression, or 3×HA-ARNT overexpression constructs, immunoprecipitated with anti-HA antibody (clone 1F5C6) ( E ) and in WM115 cells treated with 1 μM FICZ for 72 h, immunoprecipitated with IgG control (clone DA1E), anti-AHR (clone D5S6H), or anti-ARNT (clone D28F3) antibodies ( F ). G Enrichment analysis of transcription factor motifs in AHR- and ARNT-binding regions identified by ChIP-seq of SKMEL2 cells overexpressing 3×HA-tagged AHR or ARNT. Top-enriched motifs include canonical AHR response elements. H ChIP-qPCR quantification of AHR or ARNT occupancy at the CIITA promoter II (pII) region in SKMEL2 cells expressing empty vector control, 3×HA-AHR overexpression, or 3×HA-ARNT overexpression constructs. Enrichment is shown relative to input and normalized to the empty vector control. I Luciferase reporter assay using a construct containing the CIITA pII co-transfected with Renilla luciferase control into 293T cells expressing empty vector control, AHR overexpression, or ARNT overexpression constructs. vec, empty vector control. Data are represented as mean ± SD ( H - I ). Each dot represents one technical replicate from triplicate wells ( H - I ). Statistical analysis by one-way ANOVA ( H - I ); * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. vec, empty vector control

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: The aryl hydrocarbon receptor (AHR) drives human leukocyte antigen (HLA)-II expression in human melanoma

doi: 10.1186/s13046-026-03673-y

Figure Lengend Snippet: AHR-ARNT complex binds CIITA promoter II to drive HLA-II transcription. A - B Genome browser tracks showing gene CIITA mRNA expression (RNA-Seq) across the CIITA locus in A375 with sgNTC, sgAHR, or sgARNT (A) and in WM115 cells treated with 1 μM FICZ or 0.1% DMSO for 72 h (B). C - D ATAC-seq tracks showing chromatin accessibility at the CIITA locus in A375 cells with sgNTC, sgAHR, or sgARNT ( C ) and in WM115 cells treated with 1 μM FICZ or 0.1% DMSO for 72 h ( D ). E - F ChIP-seq tracks showing AHR or ARNT binding at the CIITA locus in SKMEL2 cells expressing empty vector control, 3×HA-AHR overexpression, or 3×HA-ARNT overexpression constructs, immunoprecipitated with anti-HA antibody (clone 1F5C6) ( E ) and in WM115 cells treated with 1 μM FICZ for 72 h, immunoprecipitated with IgG control (clone DA1E), anti-AHR (clone D5S6H), or anti-ARNT (clone D28F3) antibodies ( F ). G Enrichment analysis of transcription factor motifs in AHR- and ARNT-binding regions identified by ChIP-seq of SKMEL2 cells overexpressing 3×HA-tagged AHR or ARNT. Top-enriched motifs include canonical AHR response elements. H ChIP-qPCR quantification of AHR or ARNT occupancy at the CIITA promoter II (pII) region in SKMEL2 cells expressing empty vector control, 3×HA-AHR overexpression, or 3×HA-ARNT overexpression constructs. Enrichment is shown relative to input and normalized to the empty vector control. I Luciferase reporter assay using a construct containing the CIITA pII co-transfected with Renilla luciferase control into 293T cells expressing empty vector control, AHR overexpression, or ARNT overexpression constructs. vec, empty vector control. Data are represented as mean ± SD ( H - I ). Each dot represents one technical replicate from triplicate wells ( H - I ). Statistical analysis by one-way ANOVA ( H - I ); * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. vec, empty vector control

Article Snippet: After 48 h of transfection, cells that had been transduced were selected using 0.7 μg/ml (A375) or 0.6 μg/ml (WM115) of puromycin (InvivoGen #ant-pr-1) for 3 days.

Techniques: Expressing, RNA Sequencing, ChIP-sequencing, Binding Assay, Plasmid Preparation, Control, Over Expression, Construct, Immunoprecipitation, ChIP-qPCR, Luciferase, Reporter Assay, Transfection

Review

wm115 (ATCC)

Structured Review

Images

Related Articles

Cell Culture:

In Vitro:

Modification:

Similar Products

Image Search Results